OA-12 Interim Phase 2 Study Results of Durcabtagene Autoleucel (PHE885), a T-Charge™ Manufactured BCMA-Directed CAR-T Cell Therapy in Patients (pts) with r/r Multiple Myeloma (RRMM)

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01853-6

Andrew Spencer, Marc-Steffen Raab, Shinsuke Iida, María-Victoria Mateos Manteca, Michele Cavo, Paula Rodriguez-Otero, P. Joy Ho, Yunxin Chen, Paul Ferguson, Irit Avivi, Paolo Corradini, Esther Chan, Andy Chen, Bertrand Arnulf, Udo Holtick, Adam Sperling, Jufen Chu, David Pearson, Davide Germano, Ronan Feighery, Nikhil Munshi

引用次数: 0

查看原文本刊更多论文

Durcabtagene Autoleucel（PHE885）的OA-12中期2期研究结果，这是一种T-Charge™制造的BCMA引导的CAR-T细胞疗法，适用于r/r多发性骨髓瘤（RRMM）患者（pts）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.